# William H Matsui

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 140 papers | 15,793 citations | 18887 64 h-index | 18944 123 g-index |
| 142 all docs | 142 docs citations | 142 times ranked | 19699 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Wholeâ€exome sequencing identifies functional classes of gene mutations associated with bone marrow failure in pediatric Fanconi Anemia patients. European Journal of Haematology, 2021, 107, 293-294. | 1.1 | 0 |
| 2 | Hedgehog Signaling in Myeloid Malignancies. Cancers, 2021, 13, 4888. | 1.7 | 11 |
| 3 | Abstract PR-009: Targeting the sterol regulatory element-binding protein pathway in pancreatic ductal adenocarcinoma. , 2021, , . | | 0 |
| 4 | Abstract PR-004: Inhibition of focal adhesion kinase (FAK) improves pancreatic ductal adenocarcinomaâ€™s response to immunotherapy by targeting cancer stem cells (CSCs). Cancer Research, 2021, 81, PR-004-PR-004. | 0.4 | 2 |
| 5 | Organotypic culture assays for murine and human primary and metastatic-site tumors. Nature Protocols, 2020, 15, 2413-2442. | 5.5 | 40 |
| 6 | CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide. Nature Communications, 2020, 11, 798. | 5.8 | 43 |
| 7 | Biphenotypic Differentiation of Pancreatic Cancer in 3-Dimensional Culture. Pancreas, 2019, 48, 1225-1231. | 0.5 | 2 |
| 8 | Direct Interactions With Cancer-Associated Fibroblasts Lead to Enhanced Pancreatic Cancer Stem Cell Function. Pancreas, 2019, 48, 329-334. | 0.5 | 44 |
| 9 | Hedgehog/GLI1 activation leads to leukemic transformation of myelodysplastic syndrome in vivo and GLI1 inhibition results in antitumor activity. Oncogene, 2019, 38, 687-698. | 2.6 | 21 |
| 10 | Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2019, 25, 1128-1135. | 2.0 | 38 |
| 11 | IQGAP1 Maintains Pancreatic Ductal Adenocarcinoma Clonogenic Growth and Metastasis. Pancreas, 2019, 48, 94-98. | 0.5 | 6 |
| 12 | Ezrin Promotes Stem Cell Properties in Pancreatic Ductal Adenocarcinoma. Molecular Cancer Research, 2019, 17, 929-936. | 1.5 | 11 |
| 13 | Requirement of Sterol Regulatory Elementâ€Binding Protein Pathway in Pancreatic Ductal Adenocarcinoma. FASEB Journal, 2019, 33, . | 0.2 | 0 |
| 14 | Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1022-1028. | 2.0 | 29 |
| 15 | Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Nonâ€“First-Degree Related Donors. Biology of Blood and Marrow Transplantation, 2018, 24, 1099-1102. | 2.0 | 61 |
| 16 | Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2018, 24, 343-352. | 2.0 | 61 |
| 17 | Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight, 2018, 3, . | 2.3 | 140 |
| 18 | Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not Outcomes. Biology of Blood and Marrow Transplantation, 2018, 24, 2056-2064. | 2.0 | 32 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Haematologica, 2017, 102, 391-400. | 1.7 | 152 |
| 20 | Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. Blood, 2017, 129, 1389-1393. | 0.6 | 69 |
| 21 | Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2017, 23, 1903-1909. | 2.0 | 14 |
| 22 | Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 1887-1894. | 2.0 | 42 |
| 23 | Inhibition of Pancreatic Cancer Cell-Induced Paracrine Hedgehog Signaling by Liver X Receptor Agonists and Oxy16, a Naturally Occurring Oxysterol. Journal of Cellular Biochemistry, 2017, 118, 499-509. | 1.2 | 12 |
| 24 | Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide. Blood Advances, 2017, 1, 288-292. | 2.5 | 84 |
| 25 | The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma. PLoS ONE, 2017, 12, e0180181. | 1.1 | 68 |
| 26 | Cancer stem cell signaling pathways. Medicine (United States), 2016, 95, S8-S19. | 0.4 | 227 |
| 27 | IQGAP1 Scaffoldâ€“MAP Kinase Interactions Enhance Multiple Myeloma Clonogenic Growth and Self-Renewal. Molecular Cancer Therapeutics, 2016, 15, 2733-2739. | 1.9 | 10 |
| 28 | Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies. Leukemia Research, 2016, 49, 90-97. | 0.4 | 11 |
| 29 | Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation. Leukemia, 2016, 30, 1916-1920. | 3.3 | 79 |
| 30 | Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide. Leukemia and Lymphoma, 2016, 57, 666-675. | 0.6 | 11 |
| 31 | Hedgehog and retinoid signaling alters multiple myeloma microenvironment and generates bortezomib resistance. Journal of Clinical Investigation, 2016, 126, 4460-4468. | 3.9 | 35 |
| 32 | Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood, 2015, 125, 3024-3031. | 0.6 | 259 |
| 33 | Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. Science Translational Medicine, 2015, 7, 288ra78. | 5.8 | 104 |
| 34 | Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia. Science Translational Medicine, 2015, 7, 291ra96. | 5.8 | 50 |
| 35 | Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors. Biology of Blood and Marrow Transplantation, 2015, 21, 2115-2122. | 2.0 | 26 |
| 36 | Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. Journal of Clinical Oncology, 2015, 33, 3152-3161. | 0.8 | 215 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Activation of Liver X Receptors Inhibits Hedgehog Signaling, Clonogenic Growth, and Self-Renewal in Multiple Myeloma. Molecular Cancer Therapeutics, 2014, 13, 1873-1881. | 1.9 | 27 |
| 38 | Associations between serum folate and vitamin D levels and incident mouse sensitization in adults. Journal of Allergy and Clinical Immunology, 2014, 133, 399-404. | 1.5 | 11 |
| 39 | DCLK1 Marks a Morphologically Distinct Subpopulation of Cells With Stem Cell Properties in Preinvasive Pancreatic Cancer. Gastroenterology, 2014, 146, 245-256. | 0.6 | 277 |
| 40 | Granulocyte-macrophage colony stimulating factor (GM-CSF) enhances the clinical responses to interferon-Î± (IFN) in newly diagnosed chronic myeloid leukemia (CML). Leukemia Research, 2014, 38, 886-890. | 0.4 | 8 |
| 41 | Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells. Blood, 2014, 123, 725-733. | 0.6 | 59 |
| 42 | Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood, 2014, 124, 3817-3827. | 0.6 | 165 |
| 43 | NRF2-mediated Notch pathway activation enhances hematopoietic reconstitution following myelosuppressive radiation. Journal of Clinical Investigation, 2014, 124, 730-741. | 3.9 | 95 |
| 44 | Inhibiting Oncogenic RAS in Multiple Myeloma By Targeting Scaffold-ERK Interactions. Blood, 2014, 124, 2089-2089. | 0.6 | 0 |
| 45 | Targeting PYK2 Mediates Microenvironment-Specific Myeloma Cell Death. Blood, 2014, 124, 2081-2081. | 0.6 | 7 |
| 46 | Relationships between folate and inflammatory features of asthma. Journal of Allergy and Clinical Immunology, 2013, 131, 918-920.e6. | 1.5 | 16 |
| 47 | Single Copies of Mutant KRAS and Mutant PIK3CA Cooperate in Immortalized Human Epithelial Cells to Induce Tumor Formation. Cancer Research, 2013, 73, 3248-3261. | 0.4 | 33 |
| 48 | A bis-Benzylidine Piperidone Targeting Proteasome Ubiquitin Receptor RPN13/ADRM1 as a Therapy for Cancer. Cancer Cell, 2013, 24, 791-805. | 7.7 | 137 |
| 49 | Absence of Post-Transplantation Lymphoproliferative Disorder after Allogeneic Blood or Marrow Transplantation Using Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis. Biology of Blood and Marrow Transplantation, 2013, 19, 1514-1517. | 2.0 | 103 |
| 50 | Cancer stem cells in lung cancer: Evidence and controversies. Respirology, 2013, 18, 757-764. | 1.3 | 120 |
| 51 | Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia. Leukemia and Lymphoma, 2013, 54, 483-490. | 0.6 | 13 |
| 52 | Tumorigenic potential of circulating prostate tumor cells. Oncotarget, 2013, 4, 413-421. | 0.8 | 32 |
| 53 | A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome Research, 2012, 22, 837-849. | 2.4 | 236 |
| 54 | Cancer stem cells. Current Opinion in Oncology, 2012, 24, 170-175. | 1.1 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood, 2012, 120, 1877-1887. | 0.6 | 162 |
| 56 | Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood, 2012, 119, 4129-4132. | 0.6 | 67 |
| 57 | The Gamma Secretase Inhibitor MRK-003 Attenuates Pancreatic Cancer Growth in Preclinical Models. Molecular Cancer Therapeutics, 2012, 11, 1999-2009. | 1.9 | 79 |
| 58 | Molecular Pathways: The Hedgehog Signaling Pathway in Cancer. Clinical Cancer Research, 2012, 18, 4883-4888. | 3.2 | 143 |
| 59 | Chloroquine Improves Survival and Hematopoietic Recovery After Lethal Low-Dose-Rate Radiation. International Journal of Radiation Oncology Biology Physics, 2012, 84, 800-806. | 0.4 | 13 |
| 60 | Heterogeneity and Targeting of Pancreatic Cancer Stem Cells. Clinical Cancer Research, 2012, 18, 4277-4284. | 3.2 | 65 |
| 61 | Autologous Stem Cell Transplantation and Multiple Myeloma Cancer Stem Cells. Biology of Blood and Marrow Transplantation, 2012, 18, S27-S32. | 2.0 | 21 |
| 62 | Hedgehog pathway as a drug target: Smoothened inhibitors in development. OncoTargets and Therapy, 2012, 5, 47. | 1.0 | 126 |
| 63 | Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor Cells. Cancer Cell, 2012, 21, 430-446. | 7.7 | 564 |
| 64 | Biological and clinical relevance of stem cells in pancreatic adenocarcinoma. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 15-18. | 1.4 | 45 |
| 65 | Changing Paradigms in Cancer Clinical Trials. , 2012, , 227-246. | | 0 |
| 66 | High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas. Leukemia and Lymphoma, 2011, 52, 2076-2081. | 0.6 | 8 |
| 67 | Perspective: A model disease. Nature, 2011, 480, S58-S58. | 13.7 | 10 |
| 68 | The redox-sensitive transcription factor Nrf2 regulates murine hematopoietic stem cell survival independently of ROS levels. Blood, 2011, 118, 6572-6579. | 0.6 | 100 |
| 69 | Development and Maintenance of Cancer Stem Cells under Chronic Inflammation. Journal of Nippon Medical School, 2011, 78, 138-145. | 0.3 | 32 |
| 70 | Concise Review: Emerging Concepts in Clinical Targeting of Cancer Stem Cells. Stem Cells, 2011, 29, 883-887. | 1.4 | 80 |
| 71 | Characterization of chronic myeloid leukemia stem cells. American Journal of Hematology, 2011, 86, 31-37. | 2.0 | 78 |
| 72 | Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF. Leukemia Research, 2011, 35, 87-94. | 0.4 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biology and Therapy, 2011, 12, 598-609. | 1.5 | 103 |
| 74 | Phase I/II Study of Marrow Infiltrating Lymphocytes (MILs) Generates Measurable Myeloma-Specific Immunity in the Autologous Stem Cell Transplant (SCT) Setting. Blood, 2011, 118, 997-997. | 0.6 | 1 |
| 75 | The TGF- Î² Family Member Growth Differentiation Factor 15 (GDF15) Regulates the Self-Renewal of Multiple Myeloma Cancer Stem Cells. Blood, 2011, 118, 2954-2954. | 0.6 | 0 |
| 76 | Isolation of Stem Cells from Human Pancreatic Cancer Xenografts. Journal of Visualized Experiments, 2010, , . | 0.2 | 32 |
| 77 | High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood, 2010, 115, 2136-2141. | 0.6 | 107 |
| 78 | Gli1 regulates the proliferation and differentiation of HSCs and myeloid progenitors. Blood, 2010, 115, 2391-2396. | 0.6 | 102 |
| 79 | High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood, 2010, 115, 3224-3230. | 0.6 | 346 |
| 80 | Mantle cell lymphoma activation enhances bortezomib sensitivity. Blood, 2010, 116, 4185-4191. | 0.6 | 35 |
| 81 | Prognostic Significance of Tumorigenic Cells With Mesenchymal Features in Pancreatic Adenocarcinoma. Journal of the National Cancer Institute, 2010, 102, 340-351. | 3.0 | 392 |
| 82 | Cancer-Related Epigenome Changes Associated with Reprogramming to Induced Pluripotent Stem Cells. Cancer Research, 2010, 70, 7662-7673. | 0.4 | 71 |
| 83 | A Combination of DR5 Agonistic Monoclonal Antibody with Gemcitabine Targets Pancreatic Cancer Stem Cells and Results in Long-term Disease Control in Human Pancreatic Cancer Model. Molecular Cancer Therapeutics, 2010, 9, 2582-2592. | 1.9 | 83 |
| 84 | Nonmyeloablative HLA-Haploidentical Bone Marrow Transplantation with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on Outcome. Biology of Blood and Marrow Transplantation, 2010, 16, 482-489. | 2.0 | 260 |
| 85 | Tumor-Initiating Cells Are Rare in Many Human Tumors. Cell Stem Cell, 2010, 7, 279-282. | 5.2 | 205 |
| 86 | Hypoxia Increases the Expression of Stem-Cell Markers and Promotes Clonogenicity in Glioblastoma Neurospheres. American Journal of Pathology, 2010, 177, 1491-1502. | 1.9 | 306 |
| 87 | Targeting Hedgehog â€" a Cancer Stem Cell Pathway. Clinical Cancer Research, 2010, 16, 3130-3140. | 3.2 | 436 |
| 88 | Telomerase Inhibition Targets Clonogenic Multiple Myeloma Cells through Telomere Length-Dependent and Independent Mechanisms. PLoS ONE, 2010, 5, e12487. | 1.1 | 63 |
| 89 | Self-Renewal of Acute Lymphocytic Leukemia Cells Is Limited by the Hedgehog Pathway Inhibitors Cyclopamine and IPI-926. PLoS ONE, 2010, 5, e15262. | 1.1 | 75 |
| 90 | Hedgehog Signaling in Hematopoiesis. Critical Reviews in Eukaryotic Gene Expression, 2010, 20, 129-139. | 0.4 | 27 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Multiple Myeloma: A Paradigm for Translation of the Cancer Stem Cell Hypothesis. Anti-Cancer Agents in Medicinal Chemistry, 2010, 10, 116-120. | 0.9 | 39 |
| 92 | Origin of the Myeloma Stem Cell. Blood, 2010, 116, SCI-4-SCI-4. | 0.6 | 0 |
| 93 | Achaete-Scute Complex Homologue 1 Regulates Tumor-Initiating Capacity in Human Small Cell Lung Cancer. Cancer Research, 2009, 69, 845-854. | 0.4 | 158 |
| 94 | GLI1 Is a Direct Transcriptional Target of EWS-FLI1 Oncoprotein. Journal of Biological Chemistry, 2009, 284, 9074-9082. | 1.6 | 146 |
| 95 | Ligand-dependent Notch Signaling Is Involved in Tumor Initiation and Tumor Maintenance in Pancreatic Cancer. Clinical Cancer Research, 2009, 15, 2291-2301. | 3.2 | 161 |
| 96 | A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Molecular Cancer Therapeutics, 2009, 8, 310-314. | 1.9 | 250 |
| 97 | Glycosylphosphatidylinositol-anchored protein deficiency confers resistance to apoptosis in PNH. Experimental Hematology, 2009, 37, 42-51.e1. | 0.2 | 34 |
| 98 | Urothelial carcinoma: Stem cells on the edge. Cancer and Metastasis Reviews, 2009, 28, 291-304. | 2.7 | 54 |
| 99 | Cancer stem cells: controversies in multiple myeloma. Journal of Molecular Medicine, 2009, 87, 1079-1085. | 1.7 | 31 |
| 100 | DNER, an Epigenetically Modulated Gene, Regulates Glioblastoma-Derived Neurosphere Cell Differentiation and Tumor Propagation. Stem Cells, 2009, 27, 1473-1486. | 1.4 | 84 |
| 101 | Differentiation of a Highly Tumorigenic Basal Cell Compartment in Urothelial Carcinoma. Stem Cells, 2009, 27, 1487-1495. | 1.4 | 117 |
| 102 | Cancer stem cells in multiple myeloma. Cancer Letters, 2009, 277, 1-7. | 3.2 | 73 |
| 103 | Smoothening the Controversial Role of Hedgehog in Hematopoiesis. Cell Stem Cell, 2009, 4, 470-471. | 5.2 | 11 |
| 104 | Higher serum folate levels are associated with a lower risk of atopy and wheeze. Journal of Allergy and Clinical Immunology, 2009, 123, 1253-1259.e2. | 1.5 | 90 |
| 105 | Circulating clonotypic B cells in classic Hodgkin lymphoma. Blood, 2009, 113, 5920-5926. | 0.6 | 159 |
| 106 | Response: Hodgkin lymphoma stem cells. Blood, 2009, 114, 3971-3972. | 0.6 | 3 |
| 107 | Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. Leukemia Research, 2008, 32, 1439-1447. | 0.4 | 18 |
| 108 | HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2008, 14, 641-650. | 2.0 | 1,525 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance. Cancer Research, 2008, 68, 190-197. | 0.4 | 495 |
| 110 | An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Molecular Cancer Therapeutics, 2008, 7, 2725-2735. | 1.9 | 250 |
| 111 | Multiple Myeloma Cancer Stem Cells. Journal of Clinical Oncology, 2008, 26, 2895-2900. | 0.8 | 101 |
| 112 | The multiple myelomaâ€“associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. Blood, 2008, 111, 856-864. | 0.6 | 137 |
| 113 | Blockade of Hedgehog Signaling Inhibits Pancreatic Cancer Invasion and Metastases: A New Paradigm for Combination Therapy in Solid Cancers. Cancer Research, 2007, 67, 2187-2196. | 0.4 | 647 |
| 114 | Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 4048-4053. | 3.3 | 460 |
| 115 | Cancer Stem Cells: From Bench to Bedside. Biology of Blood and Marrow Transplantation, 2007, 13, 47-52. | 2.0 | 18 |
| 116 | Induction of Autologous Graft-versus-Host Disease: Results of a Randomized Prospective Clinical Trial in Patients with Poor Risk Lymphoma. Biology of Blood and Marrow Transplantation, 2007, 13, 1185-1191. | 2.0 | 24 |
| 117 | Therapeutic Implications of Leukemic Stem Cell Pathways. Clinical Cancer Research, 2007, 13, 6549-6554. | 3.2 | 20 |
| 118 | Cyclopamine-Mediated Hedgehog Pathway Inhibition Depletes Stem-Like Cancer Cells in Glioblastoma. Stem Cells, 2007, 25, 2524-2533. | 1.4 | 578 |
| 119 | Differentiation Therapy in AML. , 2007, , 293-312. | | 0 |
| 120 | Hedgehog Signaling in Normal and Malignant Hematopoiesis.. Blood, 2007, 110, 3381-3381. | 0.6 | 1 |
| 121 | Aberrant Hedgehog Signaling Represents a Novel Therapeutic Target in B Cell Lymphomas.. Blood, 2007, 110, 3582-3582. | 0.6 | 0 |
| 122 | Notch Pathway Inhibition Depletes Stem-like Cells and Blocks Engraftment in Embryonal Brain Tumors. Cancer Research, 2006, 66, 7445-7452. | 0.4 | 587 |
| 123 | Graft-versus-Host Reactions and the Effectiveness of Donor Lymphocyte Infusions. Biology of Blood and Marrow Transplantation, 2006, 12, 414-421. | 2.0 | 56 |
| 124 | Strategies to eliminate cancer stem cells: Clinical implications. European Journal of Cancer, 2006, 42, 1293-1297. | 1.3 | 52 |
| 125 | The paradox of response and survival in cancer therapeutics. Blood, 2006, 107, 431-434. | 0.6 | 146 |
| 126 | Quantitative analysis of bone marrow CD34 cells in aplastic anemia and hypoplastic myelodysplastic syndromes. Leukemia, 2006, 20, 458-462. | 3.3 | 71 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Cancer Stem Cell Targeting in Multiple Myeloma by GRN163L, a Novel and Potent Telomerase Inhibitor.. Blood, 2006, 108, 2540-2540. | 0.6 | 13 |
| 128 | Requirement for myeloid growth factors in the differentiation of acute promyelocytic leukaemia. British Journal of Haematology, 2005, 128, 853-862. | 1.2 | 34 |
| 129 | Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors. British Journal of Haematology, 2005, 130, 373-381. | 1.2 | 87 |
| 130 | Activated Marrow-Infiltrating Lymphocytes Effectively Target Plasma Cells and Their Clonogenic Precursors. Cancer Research, 2005, 65, 2026-2034. | 0.4 | 111 |
| 131 | Do Neoplastic Stem Cells Underlie the Pathogenesis of Cutaneous Lymphomas?. Archives of Dermatology, 2005, 141, 641. | 1.7 | 5 |
| 132 | Differentiation Therapy for Poor Risk Myeloid Malignancies: Results of a Dose Finding Study of Bryostatin-1 (BRYO) + GM-CSF.. Blood, 2005, 106, 2792-2792. | 0.6 | 2 |
| 133 | Cancer Stem Cells: Are We Missing the Target?. Journal of the National Cancer Institute, 2004, 96, 583-585. | 3.0 | 166 |
| 134 | Enhanced Cytotoxicity of Rituximab Following Genetic and Biochemical Disruption of Glycosylphosphatidylinositol Anchored Proteins. Leukemia and Lymphoma, 2004, 45, 795-800. | 0.6 | 16 |
| 135 | Characterization of clonogenic multiple myeloma cells. Blood, 2004, 103, 2332-2336. | 0.6 | 738 |
| 136 | Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood, 2004, 104, 2187-2193. | 0.6 | 284 |
| 137 | Multiple Myeloma Stem Cells and Plasma Cells Display Distinct Drug Sensitivities.. Blood, 2004, 104, 2476-2476. | 0.6 | 4 |
| 138 | Anti-tumour activity of interferon-alpha in multiple myeloma: role of interleukin 6 and tumor cell differentiation. British Journal of Haematology, 2003, 121, 251-258. | 1.2 | 38 |
| 139 | The role of growth factors in the activity of pharmacological differentiation agents. Cell Growth & Differentiation: the Molecular Biology Journal of the American Association for Cancer Research, 2002, 13, 275-83. | 0.8 | 12 |
| 140 | Glucocorticoid Receptor Transcriptional Activity Determined by Spacing of Receptor and Nonreceptor DNA Sites. Journal of Biological Chemistry, 1998, 273, 30081-30085. | 1.6 | 74 |